Industrial Consortium

A major M-CERSI-wide outreach and exchange involves the establishment of industrial consortia, which will build upon and cut across project themes. The CERSI Industrial Consortia program provides a vehicle for facilitating communication with industry, working toward a new level of public transparency for regulatory processes and procedures. Researchers, regulators and industry professionals can benefit from interaction and joint efforts to develop regulatory science practices that promote innovation in medical devices and pharmaceuticals. Consortia activities address broad issues, such as risk benefit, as well as more technical projects on specific topics. Industry/University collaborative spinout projects are developed with Consortia members.

Researchers, regulators and industry professionals can learn from one other in the effort to develop regulatory science practices that promote innovation in medical devices and pharmaceuticals, while also addressing critical safety concerns. One industrial consortium will focus on drugs and biologics, and the other on biomedical devices.

The M-CERSI will engage industrial experts who may give seminars and presentations and provide advice and input to researchers and scientists.  To learn more about how to enroll in the M-CERSI Industrial Consortia program, please contact us at


AdvaMed BD
Canon US Life Sciences
Lockheed Martin
MDMA Medstar Health
Siemens Waters


Director of Development for Corporations and Foundations:

Jennifer Schwartz
3218 Jeong H. Kim Engineering Building
Phone: 301-405-8289



Use of Non-Federal Funds Terms and Conditions:

All non-federal entity providing funds or in-kind contributions to the University of Maryland Center of Excellence in Regulatory Science and Innovation (CERSI) understands that: (a) contributions will be reasonably related to the costs of the collaboration with the CERSI; (b) the contributions will not result in undue influence on FDA regulatory decisions; (c) the contributions will not result in an endorsement of non-federal entity or any of its products or activities by FDA; (d) the contributions will not provide access to non-public product specific information from FDA; (e) the contribution may be publicly acknowledged by non-federal entity, but non-federal entity may not promote itself as having a relationship with FDA; and (f) FDA staff will abide by federal ethics rules regarding acceptance of gifts, honoraria, travel reimbursement and prospective employment. In particular, any FDA employee who commences employment discussions or otherwise seeks employment with a non-federal entity will immediately recuse themselves from official participation in any collaboration involving that entity and from all other particular government matters affecting the financial interests of that entity.